Dynavax Shares Down 14.5%; Co. Reported SD-101 Overall Response Rate Of 60%, Excluding 5 Patients Who Dropped Out; STAT News' Adam Feuerstein, The Top Pharma/Biotech Reporter, Noted When The 5 Patients Were Added Back To Trial, Response Rate Was 50%
Benzinga Newsdesk